These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 10916096

  • 1. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.
    Wolf WC, Yoshida H, Agata J, Chao L, Chao J.
    Kidney Int; 2000 Aug; 58(2):730-9. PubMed ID: 10916096
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats.
    Xia CF, Bledsoe G, Chao L, Chao J.
    Am J Physiol Renal Physiol; 2005 Sep; 289(3):F622-31. PubMed ID: 15886273
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats.
    Zhang JJ, Yoshida H, Chao L, Chao J.
    Hum Gene Ther; 2000 Sep 01; 11(13):1817-27. PubMed ID: 10986555
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats.
    Zhang JJ, Chao L, Chao J.
    Stroke; 1999 Sep 01; 30(9):1925-31; discussion 1931-2. PubMed ID: 10471446
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery.
    Bledsoe G, Shen B, Yao Y, Zhang JJ, Chao L, Chao J.
    Hum Gene Ther; 2006 May 01; 17(5):545-55. PubMed ID: 16716111
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats.
    Zhang JJ, Wang C, Lin KF, Chao L, Chao J.
    Clin Exp Hypertens; 1999 Oct 01; 21(7):1145-60. PubMed ID: 10513833
    [Abstract] [Full Text] [Related]

  • 16. Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice.
    Emanueli C, Salis MB, Chao J, Chao L, Agata J, Lin KF, Munaò A, Straino S, Minasi A, Capogrossi MC, Madeddu P.
    Arterioscler Thromb Vasc Biol; 2000 Jun 01; 20(6):1459-66. PubMed ID: 10845858
    [Abstract] [Full Text] [Related]

  • 17. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation.
    Li HJ, Yin H, Yao YY, Shen B, Bader M, Chao L, Chao J.
    Cardiovasc Res; 2007 Jan 01; 73(1):130-42. PubMed ID: 17137568
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries.
    Wang T, Li H, Zhao C, Chen C, Li J, Chao J, Chao L, Xiao X, Wang DW.
    Gene Ther; 2004 Sep 01; 11(17):1342-50. PubMed ID: 15175642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.